Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …

Multiple mechanisms of resistance contribute to the inevitable progression of hormone-
sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved …

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR)
signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal …

Chemotherapy using the taxanes, docetaxel and cabazitaxel, remains an important
therapeutic option in metastatic castration-resistant prostate cancer (CRPC). However …

Purpose: The availability of newly approved treatment options for metastatic castration
resistant prostate cancer is not matched with conclusive data on optimal sequencing …

Although the long natural history of prostate cancer presents challenges in the development
of novel therapeutics, major contributions have been observed recently. A better …

Abstract Treatment options for metastatic castration-resistant prostate cancer (CRPC) have
evolved with the established benefit of the novel androgen receptor (AR)-targeted agents …

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to
castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for …

Medical oncologists who treat men with castration-resistant prostate cancer (CRPC) have
seen an abundance of new agents approved by the United States Food and Drug …

Context After initiation of androgen deprivation therapy (ADT), most patients progress to
castration-resistant prostate cancer (CRPC) within 2 or 3 yr. In the USA, approximately 67 …